Researchers examine patient barriers when receiving follow-up for heart failure hospitalization.
Researchers sought to determine the rate of stroke in patients with heart failure with preserved ejection fraction without atrial fibrillation.
Recent FDA approvals include treatments for postpartum depression, RSV in infants, pediatric constipation, metastatic colorectal cancer, and iron deficiency.
Self-reported health status better for patients increasing step counts over 12 weeks.
Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment.
Researchers studied the effect of nutritional status on the association between obesity and mortality among patients with acute heart failure.
Inpefa is expected to be available by the end of June 2023.
Hemodynamic monitoring improved Kansas City Cardiomyopathy Questionnaire with CardioMEMS-HF system vs standard care
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Researchers studied the effect of gout on cardiovascular events, including CVD and heart failure, in a Black urban population.
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure.
Findings persist after adjusting for cardiovascular risk factors and socioeconomic status.
Lower county food insecurity percentage, higher county food environment index linked to lower heart failure mortality rate.
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
A committee of nephrologists and cardiologists developed 6 recommendations to improve hyperkalemia management.
Low or intermediate score on Short Physical Performance Battery linked to increased risks for composite, individual CVD outcomes.
In the US, prevalence of CV risk factors and disease set to decrease for Whites and increase for racial/ethnic minorities.
Risk for CVD, heart failure, and stroke significantly increased after adjustment for cardiovascular risk factors.
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.